VIRPAX PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7101 USD | -4.04% |
|
-8.96% | -77.82% |
| May. 22 | Maxim Downgrades Virpax Pharmaceuticals to Hold From Buy | MT |
| May. 15 | Virpax Prices Public Offering of Shares, Warrants; Shares Tumble | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 40.18 | 7.29 | 3.75 | 0.8317 | - | - |
| Enterprise Value (EV) 1 | 40.18 | 7.29 | 3.75 | 0.8317 | 0.8317 | 0.8317 |
| P/E ratio | - | -0.34 x | -0.25 x | -0.13 x | -0.31 x | -0.49 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 1,172 | 1,171 | 1,171 | 1,171 | - | - |
| Reference price 2 | 34.30 | 6.223 | 3.201 | 0.7101 | 0.7101 | 0.7101 |
| Announcement Date | 3/31/22 | 3/22/23 | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | -12.03 | -21.85 | -15.69 | -12.67 | -15.71 | -17.59 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | -21.65 | -15.19 | -12.59 | -15.71 | -17.59 |
| Net income 1 | -4.34 | - | -21.65 | -15.19 | -12.59 | -15.71 | -17.59 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -14.00 | - | -18.50 | -12.97 | -5.680 | -2.270 | -1.450 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/31/21 | 3/31/22 | 3/22/23 | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -4.122 | - | -5.904 | -7.715 | -3.102 | -1.651 | -3.239 | - | -4.684 | -3.077 | -3.122 | -3.167 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | -5.885 | -7.642 | -2.987 | -1.521 | -3.113 | - | -4.562 | -3.077 | -3.122 | -3.167 |
| Net income 1 | - | -5.137 | -5.885 | -7.642 | -2.987 | -1.521 | -3.113 | - | -4.562 | -3.077 | -3.122 | -3.167 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | - | -4.400 | -5.000 | -6.500 | -2.600 | -1.300 | -2.700 | - | -12.06 | -1.530 | -1.100 | -1.110 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/31/22 | 5/16/22 | 8/15/22 | 11/9/22 | 3/22/23 | 5/12/23 | 8/14/23 | 12/26/23 | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 3/31/21 | 3/31/22 | 3/22/23 | 3/26/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.7101
USD
Average target price
20
USD
Spread / Average Target
+2,716.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -77.82% | 832K | |
| +64.23% | 62.59B | |
| -2.31% | 41.18B | |
| +45.55% | 40.29B | |
| -8.29% | 27.9B | |
| +11.97% | 26.21B | |
| -21.16% | 19.09B | |
| +7.54% | 13.08B | |
| +25.72% | 12.26B | |
| +27.17% | 12.05B |
- Stock Market
- Equities
- VRPX Stock
- Financials Virpax Pharmaceuticals, Inc.
